Potential biomarkers in patients with systemic sclerosis (SSc). Endostatin, elastase and the soluble adhesion molecules (sICAM-1 and sVCAM-1) are potentially involved in the pathogenesis of SSc. PubMed, Int J Rheum Dis, 10/11/2017. (Also see Prognosis and Mortality)
Risk association between scleroderma disease (SSc) characteristics, periodontitis (PD), and tooth loss. This study showed that patients with SSc presented increased odds of PD and tooth loss compared to non–diseased controls and clinicians should be aware of the potential systemic health problems related to PD. PubMed, Clin Rheumatol, 10/07/2017. (Also see Periodontal Disease)
Intestinal microbiome in scleroderma (SSc): recent progress. Emerging evidence suggests that alterations in gut microbiota exist in the SSc disease state and more studies are needed to ascertain the mechanism by which these alterations perpetuate inflammation and fibrosis in SSc. PubMed, Curr Opin Rheumatol, 2017 Nov;29(6):553-560. (Also see Bowel Dysfunction and Endocannabinoid System)
Corbus Wins Expanded U.S. Patent Coverage of Anabasum Therapy for Systemic Sclerosis. Corbus Pharmaceuticals has extended its intellectual property portfolio with a new patent for its investigative cannabinoid–derived drug candidate anabasum to treat inflammatory diseases. Scleroderma News, 11/02/2017. (Also see Clinical Trials and Endocannabinoid System)
Factors associated with disease progression in early–diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. More than 40% of early–diagnosed patients with SSc–PAH had disease progression during a short follow–up time, which suggests that even mild PAH should be considered a high–risk complication of SSc. PubMed, Ann Rheum Dis, 10/23/2017. (Also see Prognosis of Pulmonary Hypertension)
Prevalence and disease–specific risk factors for Lower Urinary Tract symptoms (LUTS) in Systemic Sclerosis: an international multi–centric study. Self–reported LUTS are amongst the most frequent symptoms in SSc and are associated with digestive complaints. PubMed, Arthritis Care Res (Hoboken), 10/26/2017. (Also see Interstitial Cystitis)
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double–Blind, Placebo–Controlled, Pilot Trial. Significant decrease in expression of B–cell signaling and pro–fibrotic genes and pathways was observed in patients with improved modified Rodnan skin score in the belimumab group but not in the placebo group. PubMed, Arthritis Rheumatol, 10/26/2017. (Also see Clinical Trials)
Association between cortisol levels and pain threshold in systemic sclerosis and major depression. The effect of cortisol serum levels upon pain mechanism, in chronic inflammatory conditions warrants longitudinal studies to detect treatable variations in pain thresholds, depressive symptoms and to improve quality of life. PubMed, Rheumatol Int, 10/30/2017. (Also see Depression and Pain Management)
Assessment of Life Expectancy in Scleroderma–Associated Pulmonary Arterial Hypertension (SSc–PAH). Patients with SSc–PAH have a slightly higher mortality risk than patients with SSc–PAH with concomitant interstitial lung disease and significant differences exist between the 2 patient populations with regard to key cardiovascular markers. Rheumatology Advisor, 11/08/2017. (Also see Prognosis of Pulmonary Hypertension)
Orthopedic complications of linear morphea: Implications for early interdisciplinary care. Despite the use of systemic immunosuppressive therapy in many patients, approximately half of patients with linear morphea of an extremity have orthopedic disease. PubMed, Pediatr Dermatol, 11/09/2017. (Also see Linear Scleroderma)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: